Literature DB >> 1893912

Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats.

L Vécsei1, M F Beal.   

Abstract

In the present study the effects of kynurenine and its metabolite kynurenic acid were compared in different behavioral and pharmacological tests. Kynurenic acid administered i.c.v. resulted in ataxia and stereotypy in a dose-dependent manner (0.025-1.6 mumol). Administration of 0.8 mumol of kynurenic acid resulted in sleeping and an approximate 25% mortality of the animals. At a dose of 1.6 mumol all of the animals died within 2-5 min from cardiorespiratory failure. One hour after lower doses of kynurenic acid the behavior of the rats appeared normal (neither stereotypy nor ataxia were observed in their familiar environemnt), but their exploratory activity (0.025-0.2 mumol) was significantly lower in a novel environment (open-field box) compared to the control group. Twenty four hours after the injection of kynurenic acid the exploratory activity of the animals did not differ from the control group. Kynurenine administered i.c.v. in equimolar doses did not result in stereotypy, ataxia, sleeping or mortality of the animals although, immediately after high doses short-lasting (1-2 min) immobility was observed. The rearing activity of the high dose kynurenine-treated animals was lower 1 h after injection, but this effect disappeared 24 h after the treatment. Post-trial injection of kynurenic acid (0.2 mumol) slightly, but not significantly, inhibited the learning ability of the rats in an active avoidance paradigm. Kynurenine administered in an equimolar dose had no effect on the speed of learning, but significantly attenuated the intertrial activity of the rats. Kynurenic acid (0.2 mumol, 0.4 mumol) did not significantly inhibit the passive avoidance latency of the animals after post-trial treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893912     DOI: 10.1016/0014-2999(91)90436-t

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.

Authors:  Dénes Zádori; Gábor Nyiri; András Szonyi; István Szatmári; Ferenc Fülöp; József Toldi; Tamás F Freund; László Vécsei; Péter Klivényi
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

Review 2.  Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery.

Authors:  Flavio Moroni; Andrea Cozzi; Maria Sili; Guido Mannaioni
Journal:  J Neural Transm (Vienna)       Date:  2012-01-04       Impact factor: 3.575

3.  L-alpha-aminoadipate inhibits kynurenate synthesis in rat brain hippocampus and tissue culture.

Authors:  Y F Chang; R K Cauley; J D Chang; V V Rao
Journal:  Neurochem Res       Date:  1997-07       Impact factor: 3.996

4.  Acute Kynurenine Challenge Disrupts Sleep-Wake Architecture and Impairs Contextual Memory in Adult Rats.

Authors:  Ana Pocivavsek; Annalisa M Baratta; Jessica A Mong; Shaun S Viechweg
Journal:  Sleep       Date:  2017-11-01       Impact factor: 5.849

5.  Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice.

Authors:  Dániel Varga; Judit Herédi; Zita Kánvási; Marian Ruszka; Zsolt Kis; Etsuro Ono; Naoki Iwamori; Tokuko Iwamori; Hiroki Takakuwa; László Vécsei; József Toldi; Levente Gellért
Journal:  Front Behav Neurosci       Date:  2015-06-16       Impact factor: 3.558

6.  GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses.

Authors:  Rolando Berlinguer-Palmini; Alessio Masi; Roberto Narducci; Leonardo Cavone; Dario Maratea; Andrea Cozzi; Maria Sili; Flavio Moroni; Guido Mannaioni
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

Review 7.  Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid.

Authors:  Fanni Tóth; Edina Katalin Cseh; László Vécsei
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

8.  Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Jakob Møller Hansen; Dalia Abou-Kassem; Anna Koldbro Hansted; Kumari Ubhayasekera; Jonas Bergquist; László Vécsei; Inger Jansen-Olesen; Messoud Ashina
Journal:  Pharmacol Res Perspect       Date:  2021-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.